https://www.selleckchem.com/products/r428.html
47, 95%CI 0.28-0.81) as compared to those with IDH1 R132H mutation. Non-canonical IDH1 mutations occur in 7.9% of IDH-mutated gliomas and identify a specific subgroup of patients with an improved survival despite a lower rate of 1p19q codeletion. Data about the type of IDH mutation should be collected in clinical practice and within interventional trials as this could be a critical variable for improved stratification and selection of patients. Non-canonical IDH1 mutations occur in 7.9% of IDH-mutated gliomas and identify a specific subgro
Like
Comment
Share
